Precision medicine: Sustained response to erdafitinib in FGFR2-mutant, multiply recurrent ameloblastoma.

Katherine A Lawson-MichodChristopher H LeGhassan TraneshPenelope C ThomasJulie E Bauman

Published in: Cancer reports (Hoboken, N.J.) (2022)

Targeting the FGFR2 mutation resulted in sustained response and improved quality of life. Genomic profiling with targeted therapy for ameloblastoma appears promising, especially when surgery is technically infeasible.

Keyphrases

cancer therapy
minimally invasive
coronary artery bypass
copy number
drug delivery
surgical site infection
gene expression
wild type
dna methylation
atrial fibrillation
coronary artery disease
genome wide